Finasteride: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
imported>Gareth Leng
No edit summary
Line 1: Line 1:
{{subpages}}
In [[medicine]], '''finasteride''' (Proscar®) is "an orally active [[testosterone 5-alpha-reductase]] inhibitor. It is used as  a surgical alternative for treatment of [[benign prostatic hyperplasia]]."<ref>{{MeSH}}</ref>
In [[medicine]], '''finasteride''' (Proscar®) is "an orally active [[testosterone 5-alpha-reductase]] inhibitor. It is used as  a surgical alternative for treatment of [[benign prostatic hyperplasia]]."<ref>{{MeSH}}</ref>



Revision as of 09:16, 17 October 2010

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In medicine, finasteride (Proscar®) is "an orally active testosterone 5-alpha-reductase inhibitor. It is used as a surgical alternative for treatment of benign prostatic hyperplasia."[1]

History

Proscar brand of finasteride was approved by the Food and Drug Administration in the United States with a New Drug Application (NDA) in 1992.[2] A generic version with a AB Therapeutic Equivalence Code was approved with a Abbreviated New Drug Application (ANDA) in 200_.[3]

Pharmacology

Administration

Distribution

Metabolism

Excretion

Toxicity

Drug toxicity includes

Uses

Benign prostatic hypertrophy

For more information, see: Benign prostatic hypertrophy.

Prostate cancer prevention

Finasteride has also been found to reduce the incidence of prostate cancer in a randomized controlled trial; however, the trial reported statistical significance in the increase in the risk of high grade prostate cancer.[4] Subsequent analysis of the data suggests the incidence of high grade cancer is increased but without statistical significance.[5]

External links

The most up-to-date information about Finasteride and other drugs can be found at the following sites.


References

  1. Anonymous (2024), Finasteride (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Drugs@FDA. U S Food and Drug Administration
  3. Drugs@FDA. U S Food and Drug Administration
  4. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. (2003). "The influence of finasteride on the development of prostate cancer.". N Engl J Med 349 (3): 215-24. DOI:10.1056/NEJMoa030660. PMID 12824459. Research Blogging. Review in: J Fam Pract. 2003 Nov;52(11):833, 837
  5. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM (2008). "Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.". Cancer Prev Res (Phila Pa) 1 (3): 174-81. DOI:10.1158/1940-6207.CAPR-08-0092. PMID 19138953. Research Blogging.